Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychotic Disorders Clear all
Completed Phase 1 Interventional Results available

Nonconvulsive Electrotherapy: a Proof-of-concept Trial

NCT01065597
View directory record Official record
Conditions
Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
Interventions
Nonconvulsive electrotherapy
Device
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

NCT00403546
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d
Drug
Lead sponsor
Donald C. Goff, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Feasibility of an Early Detection Program for Early Psychosis on a College Campus

NCT03983421
View directory record Official record
Conditions
Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
15 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational

Detecting Risk of Suicide in a Pediatric Emergency Department

NCT00623493
View directory record Official record
Conditions
Adolescents, Mental Disorder Diagnosed in Childhood, Suicide Prevention
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 21 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00130676
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
Mifepristone, matching placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Pico Rivera, California • Riverside, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Results available

Improving Accessibility and Personalization of CR for Schizophrenia

NCT03576976
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Brooklyn, New York • New York, New York • Orangeburg, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

NCT00634348
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs

NCT02708940
View directory record Official record
Conditions
Depression, Anxiety, Psychosis
Interventions
Participatory technology development, Usual Care
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Examining the Impact of a Peer-Provided Psychoeducational Program for Parents: NAMI Basics

NCT04843163
View directory record Official record
Conditions
Mental Disorder, Child
Interventions
NAMI Basics
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Active, not recruiting Not applicable Interventional

Getting Out of the House: Using Behavioral Activation to Increase Community Participation

NCT06336616
View directory record Official record
Conditions
Major Depressive Disorder, Schizo Affective Disorder, Schizophrenia, Bipolar Disorder
Interventions
Behavior Activation
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Early Phase 1 Interventional

Cognitive Effects of Nimodipine in Patients With Schizophrenia

NCT03671525
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Nimodipine, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

NCT00396214
View directory record Official record
Conditions
Schizophrenia
Interventions
Bifeprunox, Quetiapine
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
69
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Active, not recruiting No phase listed Observational

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

NCT07571148
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT (xanomeline and trospium)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Sustainable Early Episode Clinic Study (SEEC)

NCT03571685
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sustainable Early Episode Clinic Model of Care
Behavioral
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

NCT00975611
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Amantadine Hydrochloride, USP, Placebo
Drug
Lead sponsor
David C. Henderson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

NCT01568216
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 747, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

NCT01929889
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

NCT03390491
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
OnTrack>TheGame (OTG), Recovery Videos (RV)
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
16 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)

NCT06961916
View directory record Official record
Conditions
Schizophrenia
Interventions
Active rTMS, Cognitive Training
Device · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of ORG 34517 for Major Depression With Psychotic Features

NCT00226278
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
ORG 34517
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2008 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCT00287820
View directory record Official record
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 19, 2026, 8:02 AM EDT